Economic Evaluations of Cancer Screening Tests in the US: A Systematic Literature Review (SLR)

Speaker(s)

Cong Z1, Goldsmith-Martin GG2, Phalguni A2, Brown AE2
1GRAIL, LLC, Menlo Park, CA, USA, 2Genesis Research Group, Newcastle upon Tyne, Tyne and Wear, UK

OBJECTIVES: Cancer screening can improve health outcomes and decrease treatment costs. This study aimed to systematically summarize economic evaluation results of screenings across multiple cancer types.

METHODS: An SLR was conducted using PICOS criteria by searching Embase, Medline, Econlit, Cochrane and Gray literature databases. US economic evaluations comparing cancer screenings vs no screenings published during 2008-2023 in English were included.

RESULTS: 73 studies were abstracted. In breast cancer screening (n=13), cost per quality-adjusted life year (QALY) gained ranged from $6,490 to $228,427, influenced by factors such as age, breast density, and screening intervals. Life year (LY) gained per patient ranged 0.016-0.211 in lifetime models. Cervical cancer screenings (n=2) were cost-effective (CE) (cost/QALY gained: $17,204-$19,321). Colorectal cancer screening tests (colonoscopy, FIT, FOBT, mt-sDNA, CTC) all had positive LY gained (e.g., colonoscopy LY gained: 0.022-0.291) and were CE/dominant in the majority of analyses (n=35). For gastric cancer, endoscopy screening was only CE among Asian Americans as a one-time surveillance; serum pepsinogen screening was CE among smokers. For head and neck cancer (n=2), nasopharyngeal screening was CE (cost/QALY gained: $113,341), and one-time oral examination dominated. Low-dose CT for lung cancer (n=8) had positive LY gained (0.0036-0.045) with various values by populations’ risk level: CE among patients with 30 pack-year smoking history; not CE among nonsmokers. Adding multi-cancer early detection tests (n=6) to usual care demonstrated CE (cost/QALY gained: <$100,000) with LY gained ranging 0.10-0.18. PSA for prostate cancer had a LY gained of 0.027-0.105, with variant CE results depending on screening protocols.

CONCLUSIONS: Cancer screenings improve life expectancy and provide good economic value in the majority of scenarios assessed, with increased value among higher risk groups.

Code

EE211

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology